NasdaqGS - BOATS Real Time Price USD

Twist Bioscience Corporation (TWST)

46.32 -0.49 (-1.05%)
At close: February 3 at 4:00:00 PM EST
46.31 -0.01 (-0.02%)
Overnight: 8:20:00 PM EST
TWST Q1 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for TWST
Chart does not reflect overnight price.
  • Previous Close 46.81
  • Open 46.62
  • Bid 46.05 x 300
  • Ask 46.46 x 200
  • Day's Range 45.00 - 48.21
  • 52 Week Range 23.30 - 54.74
  • Volume 2,202,855
  • Avg. Volume 1,463,144
  • Market Cap (intraday) 2.838B
  • Beta (5Y Monthly) 2.27
  • PE Ratio (TTM) --
  • EPS (TTM) -1.27
  • Earnings Date Feb 2, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 49.89

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

www.twistbioscience.com

979

Full Time Employees

September 30

Fiscal Year Ends

Performance Overview: TWST

Trailing total returns as of 2/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TWST
46.03%
S&P 500 (^GSPC)
1.06%

1-Year Return

TWST
12.19%
S&P 500 (^GSPC)
15.40%

3-Year Return

TWST
83.01%
S&P 500 (^GSPC)
67.24%

5-Year Return

TWST
75.62%
S&P 500 (^GSPC)
80.61%

Earnings Trends: TWST

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 103.7M
Earnings --

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
50M
100M
 

Analyst Insights: TWST

View More

Analyst Price Targets

36.00 Low
49.89 Average
46.32 Current
58.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 2/3/2026
Analyst Evercore ISI Group
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 42 -> 52
 

Statistics: TWST

View More

Valuation Measures

Annual
As of 2/2/2026
  • Market Cap

    2.87B

  • Enterprise Value

    2.77B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.21

  • Price/Book (mrq)

    6.29

  • Enterprise Value/Revenue

    7.07

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -19.56%

  • Return on Assets (ttm)

    -13.49%

  • Return on Equity (ttm)

    -16.79%

  • Revenue (ttm)

    391.56M

  • Net Income Avi to Common (ttm)

    -76.58M

  • Diluted EPS (ttm)

    -1.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    197.95M

  • Total Debt/Equity (mrq)

    24.79%

  • Levered Free Cash Flow (ttm)

    --

Compare To: TWST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: TWST

Fair Value

46.32 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch